11th Feb 2020 16:00
Director/PDMR Shareholding
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Colleen Pythian, Director of Quality and Regulation and a PDMR, acquired 25,644 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 9.70p per share today.
Following these purchases, Colleen Pythian's total beneficial interest is 25,644 Ordinary Shares, 0.07% of the issued share capital of the Company.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a. | Name | Colleen Pythian
| ||||
2. | Reason for the notification | |||||
a. | Position/status | Director of Quality & Regulation | ||||
a. | Initial notification /Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a. | Name | genedrive plc | ||||
b. | LEI | 213800ZYODIRZ87Y4K14 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||
b. | Nature of the transaction | Purchase | ||||
c. | Price(s) and volume(s) |
| ||||
d. | Aggregated information ·; Aggregated volume ·; Price
|
N/A
| ||||
e. | Date of the transaction | 2020-02-11 | ||||
f. | Place of the transaction | London Stock Exchange, AIM | ||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 | |
David Budd: CEO / Matthew Fowler: CFO |
| |
|
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)207 418 8900 | |
James Steel / Oliver Jackson |
| |
|
| |
Stanford Capital Partners Limited (Joint Broker) | +44 (0)20 3815 8880 | |
Patrick Claridge / John Howes |
| |
|
| |
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or [email protected] | |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
Related Shares:
Genedrive